Companies › SparingVision
2 active drug programs in 2 registered trials: 2 Phase 1; Ophthalmology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SPVN06 AAV-delivered RdCVF-RdCVFL gene therapy | RDCVF | Phase 1 | Retinitis Pigmentosa | Feb 2027 |
| SPVN20 Gene therapy for rod-cone dystrophy | – | Phase 1 | Retinitis Pigmentosa (RP) | Mar 2032 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05748873 | SPVN06 | Phase 1 | Retinitis Pigmentosa | Ophthalmology | Feb 2027 |
| NCT07807111 | SPVN20 | Phase 1 | Retinitis Pigmentosa (RP) | Ophthalmology | Mar 2032 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.